EBV-associated Burkitt lymphoma in Taiwan is not age-related

References

• Leoncini L, Raphael M, Stein H, et al. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classification of tumours of haemtopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 262–264.
   Google Scholar
• Miyoshi I. Burkitt’s lymphoma in Japan. IARC Sci Publ 1985; 60: 135–147.
   PubMedGoogle Scholar
• Bi CF, Tang Y, Zhang WY, et al. Sporadic Burkitt lymphomas of children and adolescents in Chinese: a clinicopathological study of 43 cases. Diagn Pathol 2012; 7: 72.
   PubMed Web of Science ®Google Scholar
• Rao CR, Gutierrez MI, Bhatia K, et al. Association of Burkitt's lymphoma with the Epstein-Barr virus in two developing countries. Leuk Lymphoma 2000; 39: 329–337.
   PubMed Web of Science ®Google Scholar
• Mansoor A, Stevenson MS, Li RZ, et al. Prevalence of Epstein-Barr viral sequences and EBV LMP1 oncogene deletions in Burkitt's lymphoma from Pakistan: epidemiological correlations. Hum Pathol 1997; 28: 283–288.
   PubMed Web of Science ®Google Scholar
• Mbulaiteye SM, Pullarkat ST, Nathwani BN, et al. Epstein-Barr virus patterns in US Burkitt lymphoma tumors from the SEER residual tissue repository during 1979–2009. APMIS 2014; 122: 5–15.
   PubMed Web of Science ®Google Scholar
• Queiroga EM, Gualco G, Weiss LM, et al. Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am J Clin Pathol 2008; 130: 946–956.
   PubMed Web of Science ®Google Scholar
• Anwar N, Kingma DW, Bloch AR, et al. The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt: epidemiologic correlations. Cancer 1995; 76: 1245–1252.
   PubMed Web of Science ®Google Scholar
• Peylan-Ramu N, Diment J, Krichevsky S, et al. Expression of EBV encoded nuclear small non-polyadenylated RNA (EBER) molecules in 32 cases of childhood Burkitt's lymphoma from Israel. Leuk Lymphoma 2001; 40: 405–411.
   PubMed Web of Science ®Google Scholar
• Gonin J, Larousserie F, Bastard C, et al. Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma. PLoS One 2011; 6: e24617.
   PubMed Web of Science ®Google Scholar
• Lenze D, Leoncini L, Hummel M, et al. The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 2011; 25: 1869–1876.
   PubMed Web of Science ®Google Scholar
• Satou A, Asano N, Nakazawa A, et al. Epstein-Barr Virus (EBV)-positive Sporadic Burkitt Lymphoma: an age-related lymphoproliferative disorder? Am J Surg Pathol 2015; 39: 227–235
   PubMed Web of Science ®Google Scholar
• Tapia G, Lopez R, Munoz-Marmol AM, et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology 2011; 59: 672–678.
   PubMed Web of Science ®Google Scholar
• Green TM, Nielsen O, de Stricker K, et al. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol 2012; 36: 612–619.
   PubMed Web of Science ®Google Scholar
• Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 2012; 7: e33813.
   PubMed Web of Science ®Google Scholar
• Chuang SS, Huang WT, Hsieh PP, et al. Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features. Histopathology 2008; 52: 427–435.
   PubMed Web of Science ®Google Scholar
• Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3460–3467.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3452–3459.
   PubMed Web of Science ®Google Scholar
• Martin-Subero JI, Harder L, Gesk S, et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 2002; 98: 470–474.
   PubMed Web of Science ®Google Scholar
• Liang DC, Yang CP, Lin DT, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 397–405.
   PubMed Web of Science ®Google Scholar
• Oyama T, Ichimura K, Suzuki R, et al. Senile EBV + B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 2003; 27: 16–26.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Jaffe ES, Swerdlow SH. EBV positive diffuse large B-cell lymphoma of the elderly. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haemtopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 243–244.
   Google Scholar
• Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005; 106:1031–1036.
   PubMed Web of Science ®Google Scholar
• Mbulaiteye SM, Biggar RJ, Bhatia K, et al. Sporadic childhood Burkitt lymphoma incidence in the United States during 1992-2005. Pediatr Blood Cancer 2009; 53: 366–370.
   PubMed Web of Science ®Google Scholar
• Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program 2008;341–348.
   PubMedGoogle Scholar
• Leucci E, Cocco M, Onnis A, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol 2008; 216: 440–450.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Martin-Guerrero I, Wagener R, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood 2014; 123:1187–1198.
   PubMed Web of Science ®Google Scholar
• Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013; 98: 1554–1562.
   PubMed Web of Science ®Google Scholar
• Frost M, Newell J, Lones MA, et al. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2004; 121: 384–392.
   PubMed Web of Science ®Google Scholar
• Ruzinova MB, Caron T, Rodig SJ. Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. Am J Surg Pathol 2010; 34: 882–891.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Xavier AC, Wahlquist AE, Hill EG. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood 2013; 121: 4861–4866.
   PubMed Web of Science ®Google Scholar
• Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. Lancet 2012; 379: 1234–1244.
   PubMed Web of Science ®Google Scholar
• Jacobson C, LaCasce A. How I treat Burkitt lymphoma in adults. Blood 2014; 124: 2913–2920.
   PubMed Web of Science ®Google Scholar
• Wildes TM, Farrington L, Yeung C, et al. Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. Ther Adv Hematol 2014; 5: 3–12.
   PubMedGoogle Scholar
• Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116–120.
   PubMed Web of Science ®Google Scholar